Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 15, 2024

Long-Term Outcomes After Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With PD-L1 Tumor Proportion Score <1%

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up
J Thorac Oncol 2024 Apr 18;[EPub Ahead of Print], SM Gadgeel, D Rodríguez-Abreu, B Halmos, MC Garassino, T Kurata, Y Cheng, E Jensen, M Shamoun, K Rajagopalan, L Paz-Ares

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading